Across TCGA pan-cancer cohorts, OR2J4P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated OR2J4P data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR2J4P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2J4P expression acts as an unfavorable survival marker, although some lineages such as GBM and BLCA show a favorable association.
OV, SARC, and LGG are the cancer types where OR2J4P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.